ACADIA Pharmaceuticals Inc.
ACADNASDAQHealthcareBiotechnology
As of Oct 16, 2026 close
- Market cap
- $3.41B
- P/E (TTM)
- 8.95
- Forward P/E
- 5.20
- Dividend yield
- -
- 52-week range
- $18.39$30.96
- Volume (live)
- -
- Avg. volume (3M)
- 2.16M
ACADIA Pharmaceuticals (ACAD) Stock Price & Financial Analysis
ACADIA Pharmaceuticals Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $18.87 - $19.76 |
|---|---|
| 52-Week High | $30.96 |
| 52-Week Low | $18.39 |
| Open | $19.76 |
| Volume (last close) | 1.67M |
| Average Volume (3M) | 2.16M |
| Revenue (TTM) | 1.14B |
|---|---|
| Net Income (TTM) | 380.48M |
| Free Cash Flow (TTM) | 46.79M |
| EPS (TTM) | $2.21 |
| Profit Margin | 33.42% |
| Operating Margin | 7.59% |
| Return on Equity (ROE) | 29.12% |
| Debt to Equity | 0.06 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 3.41B |
|---|---|
| Shares Outstanding | 172.85M |
| P/E Ratio (TTM) | 8.95 |
| Forward P/E | 5.20 |
| Price to Sales (P/S) | 2.99 |
| Price to Book (P/B) | 2.61 |
| EV/EBITDA | 26.71 |
| 50-Day MA | $25.92 |
|---|---|
| 200-Day MA | $24.08 |
| 1-Year Change | −5.65% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
ACADIA Pharmaceuticals at a Glance
As of the Oct 16, 2026 close, ACADIA Pharmaceuticals (ACAD) has a market capitalization of $3.41B. The stock trades at 8.9× trailing earnings, 5.2× forward earnings and 3.0× sales. Over the trailing twelve months it earned $380.48M on revenue of $1.14B (a 33.4% profit margin) and generated $46.79M of free cash flow. Revenue grew 11.8% year over year.
As of its latest reported balance sheet, it holds $384.99M in cash and securities against $73.85M of debt, a net cash position of $311.13M.
ACADIA Pharmaceuticals does not currently pay a dividend.
The share price is down 5.6% over the past year. At $19.12 (the Oct 16, 2026 close) it sits near the bottom of its 52-week range of $18.39 to $30.96, below its 200-day moving average of $24.08.
Based on 18 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $33.36, 74.5% above the Oct 16, 2026 close.
Frequently Asked Questions About ACADIA Pharmaceuticals
What is the current stock price for ACAD?
As of the Oct 16, 2026 close, ACAD stock trades at $19.12. The 52-week range is $18.39–$30.96, with a day range of $18.87–$19.76.
What is the P/E ratio for ACAD?
As of the Oct 16, 2026 close, ACADIA Pharmaceuticals's trailing twelve-month (TTM) P/E ratio is 8.9, meaning investors pay $8.9 for every $1 of annual earnings. The forward P/E is 5.2, reflecting analyst expectations for future earnings. ACADIA Pharmaceuticals operates in the Healthcare sector.
Does ACAD pay dividends?
ACADIA Pharmaceuticals does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for ACAD?
Based on ratings from 18 professional analysts over the last 90 days, the consensus for ACAD is Buy. The average 12-month price target is $33.36, a 74.5% upside from the Oct 16, 2026 close of $19.12.
What is the market cap of ACAD?
As of the Oct 16, 2026 close, ACADIA Pharmaceuticals's market capitalization is $3.30B, classifying it as a mid-cap company. ACADIA Pharmaceuticals operates in the Healthcare sector within the Biotechnology industry.